Skip to main content
. 2013 Jun;2(3):152–159. doi: 10.3978/j.issn.2218-6751.2012.12.08

Figure 6.

Figure 6

Hypothetical model for tumors with EGFR mutations, where erlotinib can abrogate ERK and adaptive resistance can be expected in tumors expressing BIM. Rebiopsies hours after initiating treatment will help us to understand the correct RTKs for co-targeting.